Your browser doesn't support javascript.
loading
Antihistamine effects and safety of fexofenadine: a systematic review and Meta-analysis of randomized controlled trials.
Huang, Cheng-Zhi; Jiang, Zhi-Hui; Wang, Jian; Luo, Yue; Peng, Hua.
Afiliação
  • Huang CZ; Department of Otolaryngology Head and Neck Surgery, General Hospital of Southern Theatre Command of PLA, Guangzhou, 510010, China.
  • Jiang ZH; Department of Otolaryngology Head and Neck Surgery, Shenzhen University General Hospital, Shenzhen, 518055, China.
  • Wang J; Department of Pharmacy, General Hospital of Southern Theatre Command of PLA, Guangzhou, 510010, China.
  • Luo Y; Department of Otolaryngology Head and Neck Surgery, General Hospital of Southern Theatre Command of PLA, Guangzhou, 510010, China.
  • Peng H; Integrated Hospital of Traditional Chinese Medicine, Southern Medical University, Guangzhou, 510315, China.
BMC Pharmacol Toxicol ; 20(1): 72, 2019 11 29.
Article em En | MEDLINE | ID: mdl-31783781
ABSTRACT

BACKGROUND:

As a new generation antihistamine, fexofenadine has been widely used in allergic diseases. However, there is still a lack of collective evidence regarding the antihistamine effects and safety profiles of fexofenadine relative to other antihistamine drugs and placebo. Therefore, we aimed to systematically evaluate the antihistamine effects and safety of fexofenadine.

METHODS:

An electronic literature search of randomized controlled trials (RCTs) was performed using Embase, Cochrane and PubMed from establishment to January 1st, 2018. RCTs comparing the antihistamine effects or safety (adverse events, sedative effects, and cognitive/psychomotor function) of fexofenadine with either other antihistamines or placebo for healthy subjects and patients with allergy were selected.

RESULTS:

Fifty-one studies of 14,551 participants met the inclusion criteria. When compared with the first-generation antihistamines, fexofenadine produced significantly lower adverse events frequency (OR = 0.446; 95% CI 0.214 to 0.929, P = 0.031), significantly lower sedative effects frequency (OR = 0.265; 95% CI 0.072 to 0.976, P = 0.046) and significantly less change of all cognitive/psychomotor function. When compared with the second-generation antihistamines, fexofenadine produced significantly marginal sedative effects (OR = 0.59; 95% CI, 0.38 to 0.93; P = 0.02) and significantly less change of most of the cognitive/psychomotor function. When compared with placebo, fexofenadine produced more significant antihistamine effects.

CONCLUSIONS:

Fexofenadine has a positive antihistamine effect, which is probably no worse than the second-generation antihistamines. Fexofenadine probably has a favorable safety profile, which is more likely better than that of the first-generation antihistamines. There is lack of data to support that fexofenadine has a better overall safety profile compared to the second-generation antihistamines, however, some presently available evidence on sedative effects and certain aspects of cognitive/psychomotor function favors fexofenadine. Therefore, fexofenadine may be worthy of recommendation for safety related workers.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Terfenadina / Antagonistas não Sedativos dos Receptores H1 da Histamina / Efeitos Colaterais e Reações Adversas Relacionados a Medicamentos Idioma: En Ano de publicação: 2019 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Terfenadina / Antagonistas não Sedativos dos Receptores H1 da Histamina / Efeitos Colaterais e Reações Adversas Relacionados a Medicamentos Idioma: En Ano de publicação: 2019 Tipo de documento: Article